Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 14 , ISSUE 1 ( January-February, 2022 ) > List of Articles

CASE REPORT

Nongestational Choriocarcinoma Managed by Neoadjuvant Chemotherapy and Interval Surgery: A Case Report

Richi Khandelwal

Keywords : Fertility-sparing surgery, Malignant germ cell tumor, Neoadjuvant chemotherapy in germ cell tumor, Nongestational choriocarcinoma

Citation Information : Khandelwal R. Nongestational Choriocarcinoma Managed by Neoadjuvant Chemotherapy and Interval Surgery: A Case Report. J South Asian Feder Obs Gynae 2022; 14 (1):73-74.

DOI: 10.5005/jp-journals-10006-2002

License: CC BY-NC 4.0

Published Online: 05-04-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract

Ovarian cancer is the third commonest gynecological malignancy worldwide. Among ovarian cancer, epithelial carcinoma is the commonest followed by germ cell tumor. Choriocarcinoma of the ovary can be gestational or nongestational. Pure nongestational choriocarcinoma (NGCO) of the ovary is extremely rare. Histologically, it has the same appearance metastatic gestational choriocarcinoma to the ovaries. Here is a case of 15-year-old premenarchal girl referred with abdominal distension with ascites. Among her markers, beta-hCG was 860 IU/L and imaging showed a large mass with central necrosis. USG showed an ovarian mass with empty uterus. Due to her poor ECOG status, she was given etoposide + cisplatin for four cycles post-FNAC diagnosis of choriocarcinoma diagnosis. Post-neoadjuvant chemotherapy (NACT) her beta-hCG came down to be 2.16 IU/L. She subsequently underwent right salpingo-oophorectomy with surgical staging. Postoperative period was uneventful and further two cycles of etoposide + cisplatin were planned to be given. There is only a case series of 21 cases in India where NACT was given in advanced germ cell tumor followed by fertility-sparing surgery.


HTML PDF Share
  1. Scully RE, Young RH, Clement RB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. In: Atlas of tumor pathology: 3rd Series, Fascicle 23. Washington, DC: Armed Forces Institute of Pathology; 1998. p. 169–498.
  2. Gershenson DM. Management of early ovarian cancer: germ cell and sex-cord stromal tumors. Gynecol Oncol 1994;55:S62–S72. PMID: 7530680.
  3. Talukdar S, Kumar S, Bhatla N, et al. Neo-adjuvant chemotherapy in the treatment of advanced malignant germ cell tumors of ovary. Gynecol Oncol 2014;132(1):28–32. DOI: 10.1016/j.ygyno.2013. 10.009.
  4. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. Eur Urol 2008;53(3):478–496. DOI: 10.1016/j.eururo.2007.12.024.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.